The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

A large majority of older Americans feel that health insurance—including Medicare—should cover anti-obesity medications, ...

Medicare coverage for Ozempic is not the same as Wegovy. Wegovy contains the same active ingredient as Ozempic, semaglutide, but it is FDA approved to help with weight loss. Medicare can cover ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

A new University of Michigan study shows that a strong majority of older Americans want health insurance — including Medicare — to cover weight loss medica ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Medicare does not cover anti-obesity medications ... such as type 2 diabetes. Wegovy contains semaglutide, which is also the main ingredient in Ozempic. While Ozempic does not have FDA approval ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

A new study links semaglutide, the active ingredient in Ozempic and Wegovy, to a higher risk of hair loss, especially in ...

The FBI has issued a warning about counterfeit versions of compounded weight loss drugs, which have been found to contain ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...